India, June 11 -- Glenmark Pharmaceuticals, through its wholly-owned subsidiary Glenmark Specialty S.A. (GSSA), has launched Winlevi® (clascoterone 10 mg/g cream) in several key European markets for the treatment of acne vulgaris in adults and adolescents.
The launch follows the European Commission's approval of the product in October 2025. Glenmark has commenced direct commercialization in regions including the Nordics, Central and Eastern Europe, and Spain, while introducing the product in Portugal through a strategic partner. Additional launches across Europe are also being pursued through partnership arrangements.
Winlevi® is regarded as the first topical acne treatment in more than four decades with a novel mechanism of actio...